Bausch Health Cos (BHC) Financials

Bausch Health’s latest quarter shows a sharp improvement in operating performance. For Q2 2026, revenue rose to $2.85 billion, up 12.7% from $2.53 billion in the restated Q2 2025 results and 18.7% from Q2 2024. Gross profit increased to $2.08 billion, lifting the gross margin to approximately 72.9%, compared with 69.8% in Q2 2025. Operating income reached $740 million, versus $444 million a year earlier.

Profitability also rebounded substantially. Net income attributable to common shareholders was $258 million, or $0.68 per diluted share, compared with $148 million, or $0.40 per share, in Q2 2025. This follows a $1.42 billion net loss in Q1 2026, which was driven largely by a $1.426 billion impairment charge. The absence of a comparable impairment charge in Q2 materially improved reported earnings, although investors should distinguish between recurring operating gains and the effect of unusual charges.

Cash generation strengthened considerably, while debt declined modestly. Operating cash flow rose to $670 million in Q2 2026 from $289 million in Q2 2025, and capital expenditures were $77 million, implying approximate quarterly free cash flow of $593 million. Cash and equivalents increased to $1.825 billion from $1.299 billion at the end of Q1. Total reported debt was approximately $20.7 billion, down from about $21.7 billion a year earlier, but interest expense remained high at $396 million for the quarter.

• Revenue growth has accelerated: Quarterly revenue increased from $1.94 billion in Q1 2023 to $2.85 billion in Q2 2026, although comparisons should account for seasonality and the use of restated figures.
• Margins improved: Q2 2026 gross margin was approximately 72.9%, while operating margin was approximately 25.9%, both meaningfully above Q2 2025 levels.
• Operating cash flow is robust: Q2 2026 operating cash flow of $670 million was more than double the restated Q2 2025 amount of $289 million.
• Free cash flow provides debt-service capacity: Operating cash flow less capital expenditures was approximately $593 million in Q2 2026, giving the company cash that can be directed toward debt reduction and other obligations.
• Debt declined year over year: Total short- and long-term debt fell by roughly $1 billion from Q2 2025 to Q2 2026, while cash increased by approximately $98 million over the same period.
• Q2 earnings benefited from lower unusual charges: The company reported no impairment charge in Q2 2026, compared with a $1.426 billion impairment charge in Q1 2026 and $152 million in Q4 2025. Future results may remain volatile if additional impairments or restructuring costs occur.
• Working capital remains a significant balance-sheet component: Accounts receivable and inventories totaled approximately $3.87 billion in Q2 2026, requiring continued attention to collections and inventory management.
• Leverage remains very high: Debt of approximately $20.7 billion substantially exceeds the company’s $1.84 billion of cash and restricted cash, leaving Bausch Health highly sensitive to refinancing conditions and interest rates.
• Interest expense consumes a large portion of operating income: Q2 2026 interest expense was $396 million, or more than half of operating income, limiting the amount of profit available to shareholders.
• Shareholders’ equity remains negative: Total equity and noncontrolling interests were negative $802 million at June 30, 2026, including negative common equity of $1.771 billion and accumulated retained losses of $10.832 billion.

Overall, the latest statements point to improving revenue, margins, earnings and cash generation, with some progress on debt reduction. However, Bausch Health remains a highly leveraged company with negative equity, substantial interest costs and a history of large impairment charges. Retail investors should focus on whether the stronger operating cash flow persists and whether it can support sustained debt reduction without another deterioration in reported profitability.